HCPLive Network

In Liver Cancer, Survival Linked to Low Pain Levels

Pain could be a predictor of survival in hepatocellular carcinoma (HCC), according to research reported in The Journal of Pain, published by the American Pain Society.
 
The new findings demonstrate that understanding the role of pain may be critical in treating patients with HCC. Previous studies have established that predictors of survival for primary and metastsatic liver cancer patients include an increase in upper abdominal pain. This study investigated whether pain in its own right might have prognostic significance. The authors examined a database of 3,417 patients with liver cancer who presented with and without pain. A Kaplan-Meier analysis was performed to determine the differences in survival for patients reporting pain and those who did not.
 
The authors noted that pain is associated with decreased health-related quality of life in cancer patients and also with increased disability and mood disorders. Pain, therefore, is a major component of quality of life evaluations. Diminished quality of life is associated with poorer survival in several tumor types, including HCC.
 
The data base analysis showed that pain was linked with poorer survival in liver cancer patients who presented with pain versus those who did not. The mean survival in those with pain was 325 days versus 498 days for patients who were pain-free. The authors also evaluated the impact of tumor characteristics to determine if they alone could account for the presence of pain and poorer survival rates. They reported that patients with pain had larger and more aggressive tumors and had alphafetaprotien blood levels (a proven poor prognostic factor in liver cancer) that were twice as high as in patients without pain.
 
The authors concluded that further investigation is needed to determine which quality of life factors are most predictive for survival in liver cancer patients. Whether the treatment of pain can increase quality of life and improve survival outcomes should be explored further in clinical trials.
 
Hepatocellular carcinoma is the most common primary malignant tumor of the liver, according to HCAdvocate.org. “Primary liver cancer accounts for less than 1% of all cancers in this country. It is the seventh most common cause of cancer related deaths in men and the ninth in women. However, the incidence in the United States has increased during the past two decades possibly due to a large pool of people with longstanding hepatitis C.”
 
The American Pain Society (APS) is a multidisciplinary community that brings together a diverse group of scientists, clinicians, and other professionals to increase the knowledge of pain and transform public policy and clinical practice to reduce pain-related suffering.

--

Are the findings consistent with your own experiences? Leave a comment.

Further Reading
Differential expression of long noncoding RNAs identified in prostate cancer cell lines, patient tissue samples, and patient urine samples can detect prostate cancer, according to a study published in the November issue of the Journal of Molecular Diagnostics.
For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published online Oct. 6 in the Journal of Clinical Oncology.
A Manhattan Research survey recently found that many physicians believe digital communication technologies, including mobile apps, can be used to improve patient outcomes, according to an article published Oct. 8 in Medical Economics.
A strong brand is the Holy Grail for marketers, and should be for physicians. A brand is a promise that the product or service will be consistent and reliable every time. And it differentiates the product or service from competitors. It is a means to more sales and to a premium price so everyone in search of revenue places a strong brand identity as Job 1.
The prevalence of familial pancreatic cancer (FPC) is about 9%, and patients with FPC have more precursor lesions and are less likely to smoke than patients with sporadic pancreatic cancer, according to a study published online Oct. 14 in Cancer.
The cost to implement ICD-10 were already estimated to be dramatically more expensive than initially thought. Now, with another one-year delay, practices will face more expenses.
While industry analysts expected Medicaid expansion states would see larger increases in paying customers compared to non-expansion states, the gap was far greater than predicted.
More Reading